7 results about "Myricetin" patented technology

The application discloses a three-channel fluorescence sensor array based on sulfur quantum dots and a preparation method and detection application thereof. The sensor array is composed of three kinds of sulfur quantum dots, namely C-SQDs, PSS-SQDs and beta-SQDs. When target objects exist, the three kinds of sensing units generate differentiated fluorescence responses, forming a unique "fingerprint map". By using principal component analysis to analyze the response mode, the array can successfully distinguish between structurally similar baicalein, fiscetin, myricetin, quercetin and rutin in a concentration range of 8.0-56 muM. In addition, the array can also perform semi-quantitative analysis on a single flavone compound in a range of 4.0-56 muM, and the first principal component has a good linear relationship with the logarithm of the concentration of the target object.

The application discloses a research method of a potential protein target point of Guangxi Yaoshan sweet tea against diabetic nephropathy based on proteomics, relates to the technical field of biological medicine, and solves the problem of lacking research on the target point of the action of Yaoshan sweet tea on the prevention and treatment of diabetic nephropathy from the perspective of proteomics. The method comprises the following steps: determining a characteristic active ingredient, namely myricetin, of Yaoshan sweet tea for intervention on diabetic nephropathy, obtaining a PPI network of network pharmacology of the intersection target point of the characteristic active ingredient of Yaoshan sweet tea and diabetic nephropathy; preparing a myricetin solution, preparing a cell disease model and grouping intervention, collecting and pre-treating a cell protein sample, performing mass spectrometry, pre-processing proteomic mass spectrometry data, screening a potential protein target point, identifying and analyzing an expression change trend of the potential protein target point, and analyzing a core protein target point and a key signal path. The application directly locates the key protein target point of Guangxi Yaoshan sweet tea on diabetic nephropathy from a protein expression level, which is more intuitive and more accurate.

Stabilized oils including an edible oil and an antioxidant composition comprising α-lipoic acid and least one of ascorbic acid, ascorbyl palmitate, green tea extract, lecithin, and rosemary extract or at least one of 1,2,4-benzenetriol, carnosic acid, dihydromyricetin, dihydrorobinetin, epigallocatechin, gallic acid, 3-hydroxytyrosol, myricetin, and nepodin, and methods of preparing such stabilized edible oils. The stabilized oils may have an Oxidative Stability Index (“OSI”) at 110° C. of at least 30 hours.

This invention discloses a fusion peptide with synergistic anti-allergic effects, an anti-LTB4 monoclonal antibody, and an anti-allergic drug composition thereof. The fusion peptide is composed of peptide A, which inhibits histamine release, and peptide B, which blocks mast cell activation signals, covalently linked by a linker peptide, which can synergistically inhibit mast cell activation. The anti-LTB4 monoclonal antibody can specifically bind to LTB4, blocking its mediated inflammatory response. Combining the fusion peptide, the anti-LTB4 monoclonal antibody, and myricetin, which has antioxidant activity, forms a multi-target drug composition that can synergistically inhibit allergic reactions from multiple aspects, such as inhibiting mast cell degranulation, blocking the action of inflammatory mediators, and clearing oxidative stress products. In vitro cell experiments and OVA-induced allergic asthma mouse models have demonstrated that the anti-allergic effect of this composition is significantly better than that of a single component, and it has no obvious toxicity, providing a new candidate drug for the efficient treatment of allergic diseases.

This invention belongs to the field of coking wastewater concentrate treatment, and discloses a coking wastewater membrane concentrate treatment agent and its preparation method. The treatment agent comprises the following raw materials in parts by weight: 5-15 parts ethylenediaminetetraacetic acid, 10-30 parts sodium persulfate, 20-50 parts modified cellulose, and 10-25 parts lime; wherein the modified cellulose is a composite material obtained by reacting cellulose with sulfonated myricetin at a mass ratio of 1:(2-3). The treatment agent of this invention uses modified cellulose obtained by combining cellulose and sulfonated myricetin, which can significantly improve its adsorption performance and complexing ability in wastewater treatment, and enhance its ability to remove organic matter. Through the synergistic effect of multiple components, the treatment agent of this invention can simultaneously and efficiently remove high concentrations of organic matter, high salinity, and high color from coking wastewater membrane concentrate.

The application relates to the fields of biological analysis and biological medicine and functional food technology, and particularly relates to a food source product affinity screening method for reducing blood pressure, a composition and application, the screening method injects a sample of a food source product to be detected into an ACE / ET-1 composite affinity chromatographic column for chromatographic separation, and adopts ELSD to detect the peak time of the food source product to be detected; the food source product is divided into different binding classification according to the peak time difference between the food source product and a negative control group, and the food source product combination of different binding classification is selected to obtain a food source product composition for reducing blood pressure. The application also specifically discloses the screened composition or monomer compound for reducing blood pressure, PCR / WB and HE pathology prove that the composition can down-regulate ACE / ET-1 path-related indexes, and the monomer compounds of myricetin and myricitrin can also down-regulate ACE / ET-1 related mRNA and protein expression.

The present invention pertains to the field of medical technology, specifically disclosing the pharmaceutical application of dimyricetin-based diselenide in type II diabetes. After four weeks of continuous administration, compared with the model control group, the test substances DMS-ASD and AQ-C-a demonstrated effects that were basically equivalent to the positive control drug, semaglutide injection, in reducing fasting blood glucose levels after 16 hours of fasting in db / db mice, reducing random blood glucose levels in db / db mice, inhibiting postprandial blood glucose elevations in db / db mice, decreasing the HbA1c content of glycated hemoglobin in db / db mice, and influencing body weight and food intake in db / db mice. The pharmaceutical application of dimyricetin-based diselenide in type II diabetes holds great promise.